Scientific program
Thursday 31st of March
8:30 – 9:30 Registration & welcome coffee
9:30 – 9:45 Welcome & Opening Remarks
9:45 - 10:20 Introductive lecture
Janice M. Reichert (Reichert Biotechnology Consulting LLC, USA) – Antibody therapeutics: Trends and challenges of development in indications that are not cancer or immune-mediated disorders.
10:20 – 11:20 Session 1: Anti-infectious mAbs
Invited lecture – 10:15, Matthiew Sleeman (Medimmune, UK) – Targeting pathogens in respiratory disease
Selected presentation – 10:55, Thomas Secher (Inserm U1220, France) - Preclinical efficacy of Panobacumab (KBPA101) against acute Pseudomonas aeruginosa induced pneumonia
11:20 – 11:40 Coffee break
11:40 – 12:35 Session 2: anti-cancer mAbs
Invited lecture – 11:40, Karen L. Reckamp (City of Hope, USA) - Advances in antibody-based therapeutics for lung cancer
Selected presentation – 12:15, Rita De Santis (Sigma Tau SpA, Italy) - AvidinOX for lung cancer treatment with low dose biotinylated antibodies
12:35 – 14:05 Lunch break
14:05 – 15:00 Session 3: mAbs in asthma
Invited lecture – 14:05, Bernhard Ryffel (UMR 7355 CNRS-University of Orleans, France) – Overview of mAbs in asthma. Interleukin 17 receptor A (IL-17RA) dependent allergic lung inflammation to house dust mite in mice
Selected presentation – 14:40, Harshad P. Patil (University of Louvain, Belgium) - Impact of PEGylation on biodistribution and efficacy of antibody fragments after pulmonary delivery
15:00 – 15:55 Session 4: antibody format
Invited lecture – 15:00, Joerg Adamczewski (Sanofi/Genzyme, France) - The challenges & opportunities of multispecific antibodies at the example of the IL-4/IL-13 bispecific antibody SAR156597
Selected presentation – 15:35, Jean-François Gestin (INSERM U892 – CNRS 6299 of Nantes, France) – The radiolabelled antibody: another compagnon diagnostic
15:55 – 16:20 Coffee break
16:20 – 17:50 Session 5: inhaled antibodies
Invited lecture – 16:20, Terry Sweeney (Nektar Therapeutics, US) – Inhaled antibody and antibody-based therapeutics for respiratory diseases
Invited lecture – 16:55, Rita Vanbever (University of Louvain, Belgium) - Impact of the antibody format on their fate in the lungs
Selected presentation – 17:30, Renaud Respaud (CEPR INSERM U1100- University of Tours, France) - Pulmonary delivery of monoclonal antibodies: feasibility and challenges
17:50 – 18:20 Conclusive clinical remarks
Patrice Diot- 30 minutes (University of Tours, France)
Friday 1st of April
8:30 – 9:00 Registration & welcome coffee
9:00 – 10:00 Session 6: animal models in respiratory diseases
Invited lecture – 9:00, Caroline A. Owen (Brigham and Women's Hospital, Harvard Institutes, US) - Novel animals models of COPD
Selected presentation – 9:35, Frédéric Ducancel (CEA Saclay, France) -Development, characteristics and potential of Non-Human Primates models of respiratory infections
09:55 - 11:00 Session 7: relevance of animal models
Invited lecture – 10:00, Clive Page (King’s College of London, UK) - Relevance of animal models for development of drugs for treatment of respiratory diseases
Selected presentation – 10:35, Antoine Guillon (CEPR INSERM U1100- University of Tours, France) – a novel method to monitor inhaled antibodies after lung deposition: lung microdialysis
Selected presentation - 10:50, Stéphanie Blanc (Cynbiose, France) – Development of a cynomolgus macaque model of infection with hRSV to evaluate therapeutic approaches
11:00 Invited lecture Alain Le Pape/Stéphanie Lerondel - Overview of imaging technology to explore the lungs (CIPA, Phenomin-Taam CNRS, France)
11:45 Final remarks & conclusion
12:00 Lunch
